Tenvie Announces Dosing of First Subject in Ph 1 Trial of TNV262
06 Apr 2026 //
GLOBENEWSWIRE
Tenvie Names Don O`Sullivan as Chief Business Officer
18 Feb 2026 //
GLOBENEWSWIRE
Tony Estrada, PhD, Promoted to CEO at Tenvie Therapeutics
23 Jul 2025 //
GLOBENEWSWIRE

Market Place
Sourcing Support